Navigation Links
Scientists find new way to induce programmed cell death, or apoptosis

Researchers from the Hebrew University of Jerusalem and the Weizmann Institute of Science have developed a technique to cause apoptosis, or programmed cell death, that could lead to new approaches to treating cancer.

Apoptosis is an essential defense mechanism against the spread of abnormal cells such as cancer. It is a complex process that occurs through networks of proteins that interact with each other. Cancer cells usually avoid this process due to mutations in the genes that encode the relevant proteins. The result is that the cancer cells survive and take over while healthy cells die.

The research, by graduate student Chen Hener-Katz at the Hebrew University, involved collaboration between Prof. Assaf Friedler of the Hebrew University's Institute of Chemistry and Prof. Atan Gross of the Weizmann Institute's Department of Biological Regulation. It was published in the Journal of Biological Chemistry under the title "Molecular Basis of the Interaction between Proapoptotic Truncated BID (tBID) Protein and Mitochondrial Carrier Homologue 2 (MTCH2) Protein."

The study examined the interaction between two important proteins involved in cell death: mitochondrial carrier homologue 2 (MTCH2), which was discovered in the lab of Prof. Gross, and truncated BID (tBID), which are both involved in the apoptotic process. The researchers found the regions in the two proteins that are responsible for binding to each other, a critical step in initiating apoptosis. Following their discovery, the researchers developed short synthetic protein fragments, or peptides, that mimicked the areas on the proteins that bind to each other, and by doing so inhibited this binding. In lab experiments conducted on cell cultures, this resulted in the death of cancer cells of human origin.

"These protein segments could be the basis of future anti-cancer therapies in cases where the mechanism of natural cell death is not working properly," said Prof. Friedler. "We have just begun to uncover the hidden potential in the interaction between these proteins. This is an important potential target for the development of anticancer drugs that will stimulate apoptosis by interfering with its regulation. "

Prof. Friedler is the head of the school of chemistry at the Hebrew University. His major research interests are using peptides to study protein-protein interactions in health and disease, and developing peptides as drug leads that modulate these interactions, specifically in relation to HIV and cancer. Prof. Friedler won the prestigious starting grant from the ERC (European Research Council) as well as the outstanding young scientist prize by the Israeli Chemical Society. His research was supported by a grant from the Israel Ministry of Health and by a starting grant from the European Research Council.


Contact: Dov Smith
The Hebrew University of Jerusalem

Related medicine news :

1. New York Stem Cell Foundation scientists featured for new model of Alzheimers disease
2. SIgN scientists discover dendritic cells key to activating human immune responses
3. UW scientists discover why human body cannot fight HIV infection
4. Scientists Pinpoint Antibody That May Be Specific to MS Patients
5. Scientists first to see trafficking of immune cells in beating heart
6. Scientists develop new strategy to overcome drug-resistant childhood cancer
7. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
8. Scientists at the Mainz University Medical Center gain new insights into Taspase1 function
9. Scientists develop mouse model that could lead to new therapies for liver cancer
10. Scientists Use Stem Cells to Mimic Huntingtons Disease
11. Scientists identify gene linked to facial, skull and cognitive impairment
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech North ... Gary has spent a significant amount of time in Sweden since joining PartnerTech ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani ... Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled ... Contact Center solutions targeted to the high-end enterprise contact center marketplace. , Ed ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Breg, Inc ., a ... today that it has been awarded three contracts by ... by Novation will have access to improved pricing for ... and soft goods dedicated to advancing orthopedic care.  ... aging U.S. population, rising prevalence of chronic conditions and ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ... its Janssen Pharmaceutical Companies to significantly reduce the ... who make up 74 percent of new HIV ... Announced on World AIDS Day, these new initiatives ...
(Date:12/1/2015)... 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... pain, announced today that the company will present at the ... 1-3 at the Luxe Sunset Boulevard Hotel in ... of Relmada Therapeutics, will present on Thursday, December 3, at ... . Please register at least 10 minutes prior to ...
Breaking Medicine Technology: